Biotech Values

[DewDiligence]

RVNC -29% on disclosure buried in 3Q14 PR:

http://finance.yahoo.com/news/revance-therapeutics-releases-third-quarter-210100328.html

"While we have made significant progress with RT001, the preliminary results from our ongoing open-label study suggest we still have some work to do to optimize the transfer of manufacturing to our commercial facility and increase the probability of success for our upcoming Phase 3 pivotal program.

I’ve been skeptical of RVNC’s pipeline from day one (e.g. #msg-95531872, #msg-98170259, #msg-96916488), and the disclosure above is consistent with such a view.